Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04391738
Other study ID # DEC20-095
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2020
Est. completion date September 1, 2020

Study information

Verified date May 2020
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will involve collection of pseudonymized data from hospital-based data reporting at multiple international sites. Collating data from a large volume of patients with COVID-19 admitted in ICU across multiple international sites will enable investigation of whether obesity is a risk factor for complicated from of SARS-CoV-2 in adult patients and whether this association is independent of other cardiometabolic risk factors.


Description:

The COVID-19 pandemic is characterized by a high frequency of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), who often require invasive mechanical ventilation (IMV). Body mass index (BMI) was however rarely mentioned in early clinical reports. Disease severity gradually increased with body mass index (BMI) categories among patients admitted in intensive care unit (ICU) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the need for invasive mechanical ventilation (IMV), reaching 85% in patients with class II or III obesity ( BMI > 35 kg/m2). In summary, there is an urgent need for more evidence on the specific role played by obesity in the development of COVID-19 complications, and more particularly of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)


Recruitment information / eligibility

Status Completed
Enrollment 1200
Est. completion date September 1, 2020
Est. primary completion date May 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant is aged 18 years or over - Has been admitted to ICU with COVID-19 disease. - COVID-19 disease has been confirmed by PCR for SARS-CoV-2 - Height and weight or BMI on admission has been recorded - Data has been collected in an ethical manner as part of a national database or clinical auditing process approved by the local institution or collaboration Exclusion Criteria: -There are no exclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Patients admitted to Intensive Care Unit with SARS-CoV2
Patients admitted to Intensive Care Unit with SARS-CoV2

Locations

Country Name City State
France Centre Hospitalier Régional & Universitaire de Lille (CHRU) Lille

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relationship between body mass index (BMI) and SARS-CoV-2 The primary objective of this study is to investigate the relationship between obesity, as determined by body mass index (BMI), and severe pneumonia, as defined by the need of invasive mechanical ventilation ( IMV), among patient admitted in ICU for SARS-CoV-2, across multiple centers, in multiple countries. 3 months
Secondary Associations between BMI and outcomes is independent of the known cardiometabolic risk factors Investigate whether the associations between BMI and outcomes is independent of the known cardiometabolic risk factors, hypertension, diabetes, dyslipidemia, and current smoking. 3 months
Secondary Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation 3 months
Secondary Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Terminated NCT04435457 - Cardiovascular Implications of COVID-19
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A
Completed NCT04369794 - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Phase 4
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04542850 - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 N/A
Completed NCT04382040 - A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Phase 2
Completed NCT04378582 - Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT04383587 - Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers N/A
Recruiting NCT04402814 - IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
Completed NCT04395924 - Maternal-foetal Transmission of SARS-Cov-2
Completed NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2
Completed NCT04425889 - COVID-19 Antibodies Among Healthcare Workers
Not yet recruiting NCT04405492 - Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19 N/A